iFabric-Corp-Provides-Update-On-Covid-19-Efficacy-Testing

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

IFABRIC CORP PROVIDES UPDATE ON COVID-19 EFFICACY TESTING

MARKHAM, ON / ACCESSWIRE / April 2, 2020 / iFabric Corp. ("iFabric") (TSX:IFA), today provided the following update with regard to efficacy testing of PROTX2 treated fabrics against COVID-19:

"I am pleased to announce that efficacy testing of fabrics treated with the anti-viral variant of our PROTX2 formulation will commence shortly" said Hylton Karon, President and CEO of iFabric. "Our testing will be conducted at a top South Korean laboratory, as we were unable to locate any laboratories in North America that currently have availability of the necessary cultures, despite the current pandemic. We would anticipate receiving the initial test results within a period of a few weeks," continued Mr. Karon.

"Although prior testing of our PROTX2 formulation against the Norovirus and H1N1 viruses showed exceptional efficacy this does not automatically guarantee success against COVID-19, due to the unique characteristics of different viruses" stated Mr. Karon.

In light of the severity of the COVID-19 outbreak, the Company also confirms that it has initiated a second test against the human Coronavirus which, according to our experts, has similar physical make-up to the COVID-19 virus. This test will be conducted at a testing facility in the United States and should be concluded in about three weeks.

The Company will release the test results as they become available.

"At the same time, we are currently reviewing regulatory provisions in the United States that allow for expedited approvals or exemptions in emergency situations of products such as those treated with PROTX2" concluded Hylton Karon.

About iFabric Corp.

Headquartered in Markham, Ontario, iFabric Corp www.ifabriccorp.com currently has 26.2 million shares issued and outstanding. Through its wholly-owned subsidiaries, Intelligent Fabric Technologies (North America) Inc. ("IFTNA") and Coconut Grove Pads Inc. ("Coconut Grove"), the Company offers a variety of products and services in both of its strategic divisions:

IFTNA is focused on performance apparel as well as proprietary chemical formulations that render fabrics, foams, plastics and numerous other surfaces intelligent, thereby improving the safety and well-being of the consumer.

Coconut Grove, operating as Coconut Grove Intimates, is a designer, manufacturer, distributor, licensor and licensee of ladies intimate apparel products and accessories.

Forward looking information

Forward-looking statements provide an opinion as to the effect of certain events and trends on the business. Certain statements contained in this news release constitute forward looking statements. The use of any words such as "anticipate," "continue," "estimate," "expect," "may," "will," "project," "should," "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking information includes, but is not limited to, statements with respect to the efficacy testing of the Company's products and results and timing thereof as well as the review of the approvals of the Company's products. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking information. These risks include, but are not limited to, those associated with our capacity to finance our activities, the adequacy, timing, and results of testing of our products, the regulatory approval process, competition, market acceptance of the Company's products, the strength of intellectual property, the success of research and development programs, reliance on subcontractors and key personnel, and other risks and uncertainties detailed from time-to-time in our filings with the Canadian securities regulators.

The Company cannot provide any assurance that forward-looking statements will materialize. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or any other reason except as required by applicable securities laws.

The forward-looking statements contained in this press release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

FOR FURTHER INFORMATION, please contact:

Hilton Price, CFO
Tel: 647.465.6161
Email: [email protected]
Gary Perkins - Investor Relations
Tel: 416.882.0020
Email: [email protected]
Jean-François Dubé (Québec) - Investor Relations
Tel: 514.233.9551
Email: [email protected]

SOURCE: iFabric Corp.



View source version on accesswire.com:
https://www.accesswire.com/583702/iFabric-Corp-Provides-Update-On-Covid-19-Efficacy-Testing

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).